Macular Edema Clinical Trial
Official title:
Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion
Imaging of retinal morphological changes with time secondary to laser treatment as assessed with high definition optical coherence tomography (OCT). Furthermore changes in retinal function as an effect of treatment will be documented by visual acuity testing using ETDRS charts and microperimetry. The change in vascular leakage will be assessed by performing fluorescein angiography, flare counts will be performed monthly.
Hypertension and diabetes are widespread diseases in our modern society and due to the
comfortable, but often unhealthy "western world" lifestyle, the population suffering from
its consequences is constantly growing. Vascular pathologies affect the body's entire
vascular system subsequently including the circulation and vessels in the eye. For these
reasons, after diabetic retinopathy and vein occlusions rank among the most common vascular
disorders of the retina, with the highest incidence in a population over the age of 60. As
to prevent severe vision loss due to complications induced by these angiopathies, panretinal
or segmental laser coagulation is recommended as standard treatment of proliferative
retinopathy. So far patients who undergo panretinal coagulation typically receive between
1200 and 1500 lasers spots in two to four sessions over the course of 2 to 4 weeks. Clinical
guidelines recommend not exceeding the number of more than 900 applied laser spots per
session, due to the development of possible reversible exudative reaction e.g. macular
edema. However, the performance of a panretinal photocoagulation is so far a time consuming
procedure which is generally painful for the patient. For these reasons new laser systems
were developed aiming to solve these obvious drawbacks. Main improvement of these systems is
the reduction of the laser burn durations per spot and to enable therefore the rapid
application of a large number of spots in a preset pattern. Treatment with reduced pulse
duration is associated with less pain for the patient and, compared to several sessions
requiring about 30 minutes each when using a conventional laser system, treatment time for a
complete panretinal treatment could be significantly reduced. The PASCAL® Laser (Pattern
Scan Laser, OptiMedica® Corporation, Santa Clara, CA, USA) is a new commercially available
laser system confirming all these requirements.
As the first study part (group I and II) we propose a controlled randomized comparison of
single session to conventional multisession panretinal laser treatment, using the Pascal
laser system for the single-session protocol and the Pascal laser system or the conventional
laser system for the multi-session protocol. Development and regression of a retinal
exudative reaction and the eventual onset of transient macular edema will be observed and
documented. The morphological changes within the retina induced by laser burns will be
imaged mainly using optical coherence tomography techniques. In regard to determine the
lowest laser intensity as possible to produce a visible morphologic effect within small
retinal areas different laser intensities will be used for photocoagulation of retinal
segments to show the effect of a "sub-threshold" and gentle laser burn.
As a second study part (group III), grid pattern laser coagulation will be performed in a
conventional way using the Pascal laser system. In a small area of the retinal perifoveal
zone showing macular edema, morphologic effects of photocoagulation using titrated low, sub
threshold or threshold laser energy will be analyzed using OCT.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04292912 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
|
Phase 1 | |
Recruiting |
NCT05976139 -
Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies
|
N/A | |
Completed |
NCT03660345 -
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
|
Phase 3 | |
Completed |
NCT03660371 -
ILM Peeling in PDR Patients Undergoing PPV for VH
|
N/A | |
Completed |
NCT01660802 -
Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
|
Phase 3 | |
Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
Completed |
NCT04592419 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Completed |
NCT02623673 -
Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema
|
N/A | |
Terminated |
NCT01946399 -
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
|
N/A | |
Completed |
NCT01428388 -
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
|
N/A | |
Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
Recruiting |
NCT01023113 -
To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation
|
N/A | |
Terminated |
NCT00918554 -
Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis
|
Phase 4 | |
Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT00970957 -
Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 3 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00668239 -
Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser
|
N/A | |
Completed |
NCT00411970 -
20- Versus 23- Gauge System for Pars Plana Vitrectomy
|
Phase 4 | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 |